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                                                 INTRODUCTION 
HEAD AND NECK CANCER – WORLD SCENARIO 
Head and neck cancer is a common disease worldwide. The prevalence varies 
among different regions of the world and mirrors the occurrence of risk factors for 
head and neck cancers . The  chronic exposure of  risk factors of head and neck cancer 
to upper aerodigestive tract mucosa leads to cancer or less commonly to field 
cancerisation , a process of premalignant dysplastic lesions that are at high risk of 
progression to cancer  [1 ].  
EPIDEMIOLOGY 
INCIDENCE TRENDS 
 Head and neck cancer affects 550,000 individuals per annum worldwide . 
Males are more commonly affected than females in a ratio that varies from 2:1 to 4: 1. 
The annual incidence rate among males is 20 per 100,000 in the Indian subcontinent, 
France, Hong Kong , Central and Eastern Europe, Spain, Italy, Brazil and among  
African American males [2 ]. Head and neck cancer accounts for 3 % of all cancer 
burden in the United states with 55,000 annually affected individuals with a mortality 
of 12,000 per year . The incidence rates for  cancer sites related to HPV infections, 
such as the oropharynx, tonsil, and base of the tongue, is increasing among young 
adults in the United States and in other developed countries ( 1983-2002) [3 ]. The 
impact of HPV induced oropharyngeal cancers on overall incidence trends is unclear. 
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INCIDENCE OF ORAL CANCER AMONG 100,000 MEN-GLOBOCAN 2012 
 
INCIDENCE OF ORAL CANCER AMONG 100,000 WOMEN- GLOBOCAN 
2012 
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RISK FACTORS INFLUENCING EPIDEMIOLOGICAL PATTERNS 
 There is a substantial variation in the distribution of sub sites influenced by risk 
factor exposure. The role of  risk factors like smoking, alcohol , smokeless tobacco 
and HPV infection is uniform worldwide. Oral cavity cancers predominate in the 
Indian subcontinent,  nasopharyngeal carcinomas are common in Hong Kong, China, 
Taiwan and Malaysia,   while oropharyngeal sites occur in other populations [3 ] . The 
relative contribution of risk factors varies with sub site and  geographic region. 
Worldwide, smoking accounts for 42% of deaths from cancers of the oral cavity  and 
alcohol consumption for 16% of the deaths [3]. Smokeless tobacco products and betel 
quid with or without tobacco are the major risk factors for oral cavity cancer in  India 
and south east Asian countries [ 3] . HPV infection and associated oropharyngeal 
cancers predominantly affect the young male  and is also associated with decreasing 
lung cancer incidence in this group. 
GLOBAL MORTALITY TRENDS  
 Oral cavity cancer mortality rates among males decreased signiﬁcantly in most 
countries, including those of Europe and Asia, over the past decade, but rates 
continued to increase in several Eastern European countries, including Hungary and 
Slovakia. The increase in female death rates in most European countries  reﬂects the 
ongoing tobacco epidemic [4 ]. This contrasts with the decreasing trends at all ages for 
both males and females in the United States and United Kingdom, where the tobacco 
epidemic began and declined earlier. Data from RTOG -0129 and 0522 confirm that 
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HPV associated oropharyngeal cancers have favorable overall survival compared to 
tobacco induced cancers [4 ] . 
INDIAN SCENARIO 
THE CANCER REGISTRY 
 True estimate of cancer related epidemiological data has been traditionally 
deficient in India.  The National cancer registry programme started in 1982 with just 
three population  and hospital based registries each, has today expanded to 28 
population based and 7 hospital based registries providing entire cancer related 
epidemiological data. Information so accrued  reflects only the “Tip of iceberg 
phenomenon as the programme has only one rural registry . Hence the only optimistic 
information that can been extracted from the registry  programme for health care 
modification is by observing the time trends rather than absolute data . Interpretation 
of incidence data from a few select registries  as a tool for assessing disease burden 
may be flawed , nevertheless appears to be the only available resource .  
 Combined as a group, head and neck cancers continues to be the most common 
cancer in India. Nationwide  oral cavity cancers predominate followed by tongue 
cancers in most registries [5]. The north eastern registries record pharyngeal cancers 
as the dominant  site followed by oral cavity, the reasons for this discrepancy are 
unknown. Nasopharynx is the rarest sub site with a contribution of 0.2 % to 2 % to 
head and neck cancers. Tobacco in all forms and alcohol are the commonest risk 
factors for all head and neck sub sites, in addition betel nut quid is an established risk 
factor  in oral cavity cancers [6]. HPV induced oropharyngeal cancer epidemic well 
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recognized in developed nations is yet to be studied in India due to cost feasibility  
and lack of diagnostic facilities  for this risk factor . 
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Proportion of head & neck cancers to all cancer sites -INDIA 
 
Proportion of specific Head & neck subsites from among the registries 
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CANCER  TRENDS IN INDIA 
 Oral cavity cancers have an age standardized incidence rate of more than 20 
per 100,000 in India. The incidence increases with age in both sexes. The life time risk 
is estimated at 10 % by 75 years [7 ]. This  site alone accounts for 30 % of head and 
neck cancer burden in Indians . Incidence data may vary as much as 4 fold among the 
registries and reflect heterogenicity in sampling, study design, data collection 
methodology, disease definition and registration [7 ]. Lung and oral cavity cancers 
have shown an increasing trend particularly among males in some registries but 
remained stable in others over a period of 15 yrs. A small sex specific decrease in 
female head and neck cancers relative to age is noted perhaps reflecting lifestyle 
modifications [8] . 
 
Oral cavity and lip cancers are the third leading cause of cancer deaths in India. 
The age standardized mortality rates varying between 5.2 – 7.5 per 100,000 [8 ] .  
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INCIDENCE RATES FOR ORAL CAVITY CANCERS IN INDIA 
 
MORTALITY RATES FOR ORALCAVITY & LIP CANCERS – GLOBOCAN 2008 
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FUTURE PROJECTIONS AND ITS IMPLICATIONS 
Approximately 12% of global deaths are  due to cancer, and in a few years, it is 
projected to increase from about 6 to 10 million [9]. In the USA, cancer incidence and 
mortality have declined due to improved health infrastructure, successful   health 
education and awareness programs  translating into effective prevention, early 
detection and  treatment.  Unfortunately 62% of global cancer burden increase is 
estimated in developing countries with deprived health care systems.  
It is estimated in India that 0.8 million new cancer cases would be detected 
with 0.55 million deaths annually .The United nations “world population prospects” , 
the  2008 revision predicts oral cavity and lip cancer burdens in India would double by 
2020 and escalate beyond 125,000 cases by the year 2030 [9]. Cost effectiveness 
studies have proven that effective oral cancer screening could be performed at $ 6 
person and incremental cost per life year saved was $835 and $ 135 for high risk 
individuals [10]. This data  when interpreted with the fact that 80 % of disease in India 
presents in advanced stage emphasizes the fact that early identification can be 
curative,  and offers encouraging prospects for disease burden control in future. 
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REVIEW OF LITERATURE 
EVALUATION OF HEAD AND NECK CANCERS  
A : INITIAL EVALUATION :  
1. Thorough history 
2. Inspection and palpation of oral cavity and oropharynx 
3. Indirect laryngoscopy 
4. Anterior Rhinoscopy 
5. Neck examination  
6. Flexible laryngoscopy ( base tongue and laryngopharynx )      
7. Panendoscopy - symptom directed -yield of 2.4 to 5 % 
  If extensive dysplasia in smokers/alcoholic 
B :  Evaluation under anesthesia : Palpation, extent assessment and biopsy 
C : Fine needle aspiration (FNA) : This technique has high sensitivity and specificity 
and a diagnostic accuracy that ranges from 89 to 98 %. Non diagnostic aspirations 
occur in 5 to 16 %  commonly in cystic neck masses. It is invaluable in the evaluation 
of unknown primary [11,12 ] .Fine needle aspiration  of a suspected involved lymph 
node in  an established primary tumor may provide relevant information when clinical 
and imaging evaluation of neck lymph nodes is equivocal or would change the clinical 
treatment approach (eg., RT field or dose )[13].  Ultrasound-guided FNA compared to 
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neck CT  is comparable in overall accuracy (88 and 85 %) , while clinical palpation is 
only 69 % accurate in predicting nodal metastatic disease [14 ]. 
D : IMAGING STUDIES 
A varied list may be recommended with the following goals  
           1. Accurate T assessment  - Size/volume assessment , bone involvement 
- ,Differentiating advanced and very advanced 
disease  
           2. Evaluation of nodes in impalpable sites /post radiotherapy neck / obese  
              patients 
          3. Metastatic evaluation  
          4. Second primary tumors 
         5. Planning reconstruction 
ULTRASOUND NECK: 
In practice USG as a head and neck cancer imaging modality has a very limited 
role. It is primarily done in the initial evaluation of an asymptomatic primary tumor 
presenting with a neck nodal swelling,carcinoma of unknown primary and suspected 
thyroid carcinoma with nodal deposits .USG neck is also helpful in the evaluation of 
clinically node negative neck of obese or irradiated patients.  Perhaps the best 
application of USG neck is to enhance the yield of needle biopsy techniques. In fact 
USG guided fine needle or core biopsy is the best diagnostic modality in proving 
secondary deposits from head and neck or thyroid cancers. The sensitivity and 
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specificity are in excess of 90 % for this indication .In spite of its easy availability and 
lack of radiation exposure, the results are hugely operator dependent with inter 
observer variability[14] . 
CT scan : 
CT scan identifies tumors based on enhancement or anatomic distortion. CT 
provides greater spatial resolution, and by faster acquisition times eliminates motion 
artifacts. It is ideal for the evaluation of bone destruction. Modern MD -  CT 
technology allows reformatted images essential for planning reconstruction [15].  
CT scan is very informative for the following  
1. Extent of tumor infiltration into tongue musculature, however MRI scans 
are more reliable for this indication 
2. Mandible involvement  
3. Assessment of third dimension of tumor for accurate tumor size/volume  
calculation   
4. Invasion of the preepiglottic space, laryngeal cartilage, paraglottic space 
and subglottic extension 
5. Evaluation of retropharyngeal, parapharyngeal, upper mediastinal, and 
paratracheal nodes 
6. Bone and cartilage invasion  
Imaging by CT  is complementary to the clinical examination for the staging of 
the neck lymph nodes[16]. CT  criteria of a secondary metastatic node is a node, 
greater than 10 to 11 mm in short axial diameter , rounded in shape with loss of fatty 
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hilum, central necrosis and  contrast enhancement. Extracapsular spread of nodal 
metastasis is a poor prognostic factor  and is detected by irregular border of the lymph 
node and  infiltration of adjacent fat planes [17]. 
MRI SCAN  
MRI provides superior soft tissue definition compared with CT  and  provide 
information that  complements CT.  MRI scans  provide accurate definition of tumors 
of the tongue and are better than CT at discriminating tumor from mucus (paranasal 
sinus) and in detecting bone marrow invasion[18]. MRI is useful for evaluation of  
non-ossified cartilage which can be challenging with CT imaging .MRI might miss 
early cortical bone erosion but detects early marrow invasion [19]. 
MRI scan is particularly suited for               
1. Skull base invasion 
2. Intracranial extension  
3. Parapharyngeal tumors/extension 
4. Sinus malignancies and tongue cancers 
5. Perineural invasion 
MR imaging sequences for head and neck imaging include non-contrast enhanced 
T1-weighted images, contrast-enhanced T1-weighted images with fat suppression, and 
T2-weighted images with fat suppression. Images in axial and coronal plane are 
essential. Slice thickness of  5 mm appropriate for most scenarios and 3 mm for skull 
base and perineural spread [20]. 
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PET / PET – CT SCANS  
PET scans use  injected positron-emitting radionuclides, like  fluorine-18  that 
are taken up by metabolically or functionally active tissues. PET images are created 
by detecting these emissions by an array of detectors and then using reconstruction 
techniques to create a three dimensional image [21]. The most commonly used agent 
is 18F-flourodeoxyglucose (FDG) which is taken up into cells in varying 
concentrations based on the relative metabolism of different tissues. It is  specific for 
tumors as metabolic rates are very high in most malignant tumors [22]. 
A major limitation of  PET is  poor spatial resolution, with  difficulty in localizing 
anatomical origin of pathology . This issue can be  partially resolved with integrated 
PET-CT imaging [23]. This imaging modality has a role in the following scenarios 
1. PET scans are as sensitive and specific as CT and MRI in detecting primary 
tumors.  
2. PET is superior to both CT and MRI for detecting  nodal and distant metastases 
3. Detection of Second primary tumors 
4. Follow up imaging post CRT at 12 weeks after treatment   
The value of PET is uncertain for patients with a clinically negative (N0) neck, and 
in practice has  not replaced  surgical staging by neck dissection [24].The NCCN 
version 2014  and ESMO recommend PET-CT for the following indications 
     1, stage III and IV disease – optional 
     2, assessment of neck disease after concomitant CRT 
     3, Equivocal conventional imaging  
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TREATMENT POLICY OF HEAD AND NECK CANCERS 
Early stage disease - oral cavity cancers 
  
 
  
Locally advanced  disease - oral cavity cancers 
 
 
 
 
 
 
 
 
 
Stage I & II lesions 
Surgery or Radiation 
Stage III & IV A,B 
Resectable Un resectable 
Surgery ± reconstruction 
Definitive CRT 
Adjuvant RT or CRT Surgery for salvage 
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Treatment of oro pharyngeal cancers  
 
 
 
 
 
Treatment of laryngeal & hypopharyngeal cancers 
 
 
 
 
 
 
 
 
 
Surgery or RT 
Stages I- IV A, B 
Definitive CRT 
Salvage surgery 
Accurate staging 
Stage I&II lesions 
RT or conservative 
surgery 
Stage III & IV A,B lesions 
 
Surgery Definitive CRT 
Salvage surgery Adjuvant CRT 
T1 & selected T2 
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RISK STRATIFICATION IN HEAD AND NECK CANCERS 
THE RATIONALE 
Treatment of  cancers require accurate risk stratification  to determine the type 
and extent of therapy and this may influence expected clinical outcome. In addition to 
TNM staging, some clinical and pathologic factors not routinely incorporated into the 
staging system have been shown to influence survival outcome and response to 
therapy [25]. These prognostic factors  merit attention as a relationship with disease 
free and overall survival have been demonstrated. Factors specifically related to local 
recurrence may alter treatment with wider surgical resection, radiotherapy dose 
escalation, altered fractionisation or the use of a boost to the primary tumor bed [25]. 
Factors predicting regional recurrence may prompt prophylactic neck dissection or 
radiotherapy in the clinically node negative neck or dictate the type of neck dissection 
selected in patients with significantly enlarged neck nodes. Finally, factors correlating 
to distant metastases might prompt aggressive screening for synchronous distant 
metastases before local-regional treatment or influence the decision to offer systemic 
therapy [25]. 
A myriad of variables have been studied for prognostic significance and 
include diverse factors like genetic or molecular factors to patient related or disease 
related features. A classification of the prognostic factors is presented below 
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CLASSIFICATION 
The prognostic factors are categorized as follows as related to 
 A,  The primary tumor related 
 B, The regional cervical lymph nodes 
C,  Patient demographics 
D,Comorbidity 
E, Molecular factors 
PRIMARY TUMOR RELATED PROGNOSTIC DETERMINENTS: 
Tumor size 
The primary determinant of T stage is maximum tumor diameter and is an 
important risk factor for the presence of concomitant nodal metastases, local 
recurrence, and poor survival. Magnano et al. found that T stage was a consistent, 
independent predictor of pathologically positive cervical lymph nodes [26]. Pathologic 
maximal tumor diameter has been shown to predict local recurrence in tumors arising 
from the lower lip, oral cavity, oropharynx, and larynx. Most studies  have shown a 
significant univariate association between  tumor diameter and survival[27,28,29,30]. 
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Tumor Thickness 
The relationship between tumor thickness and risk of concomitant cervical 
lymph node metastases has been confirmed in multiple studies. The critical thickness 
above which the risk of nodal metastasis increases varies substantially, depending 
upon the specific anatomic site involved perhaps due to variation in density of 
lymphatic channels. For most subsites the critical thickness ranges from 3 to 5 mm 
[31]. Clark et al reported that the risk of occult nodal metastasis was 10% in tumors of 
< 5 mm thickness, compared to 46% risk if the tumor thickness was > 5 mm[32]. 
Woolgar et al demonstrated in tongue carcinomas the mean reconstructed thickness of 
tumors with pathologically positive cervical lymph nodes was 19 mm, compared to 10 
mm in patients without metastases. They concluded tumors with a large mucosal 
surface area but minimal invasion may not be at increased risk of nodal metastases 
consequently tumor staging by size alone might overestimate the likelihood of 
concomitant nodal disease [33,34,]. Tumor thickness may be a predictor of nodal 
metastasis in tongue cancers in addition to tumor size [35]. 
Tumor volume 
Computation of tumor volume by  CT scan may be an independent prognostic 
variable as it offers best 3-D evaluation of tumor burden. Mancuso et al in supraglottic 
cancers  found that tumor volume calculated from pretreatment CT scans was an 
independent predictor of local control, with local control rates of 89% in tumors < 6 
cm  ᵌ versus 52% for tumors ≥6 cm  ᵌ [36].This has been validated by multivariate 
analysis  in a study  by Hermans et al [37]. Hence calculation of tumor volume by 
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pretreatment diagnostic imaging may provide important prognostic information that 
can supplement traditional clinical staging for laryngeal tumors[38]. 
Grade of Tumor 
Pathologists have long recognized the potential prognostic significance of 
tumor grading. Several classification of tumor histology have been devised by 
Broders, Jakobsonn and Crazmann  but none has been validated in multivariate 
analysis.  In 1987 Anneroth et al. reviewed efforts to devise a malignancy grading 
system and proposed a grading scheme consisting of six morphologic features: degree 
of keratinization, nuclear polymorphism, number of mitoses, pattern of invasion, stage 
of invasion, and lymphoplasmacytic infiltration[39].  Bryne et al. applied Anneroth’s 
grading system and validated it in oral cavity cancers as the invasive cell grading. 
Patients with a total malignancy score between 5 and 10 experienced a 57 % 5-year 
survival, compared to a 19 % 5-year survival in patients with malignancy scores of  
>10 . Invasive cell grading  has also been  shown to strongly predicts the presence of 
occult cervical metastases and extracapsular extension [41,42]. 
In addition to grade certain other histologic features  contribute  strongly to 
prognosis. Spiro et al. observed oral tongue SCCs with a high-grade pattern of 
invasion were more likely to present with concomitant nodal metastases, develop 
distant metastases, and result in death. In oral cavity cancers  mandibular invasion 
with high- grade invasion pattern increases the rate of mandibular margin positivity, 
local recurrence and a fourfold  risk of death on multivariate analysis [43]. 
Lymphoplasmacytic infiltration of the tumor bed with CD 4 lymphocytes is a good 
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prognostic variable as reported by Hans et al. [44]. The tumor histological type and its 
variants correlate with treatment sensitivity and hence to survival. Basaloid SCC 
(BSCC) is a rare variant of SCC that has been traditionally associated with good 
chemotherapy and radiosensitivity, with equivalent loco regional control than 
“typical” SCC, but with higher risk of distant metastases [44].  
Perineural spread (PNI) 
Infiltration of perineural spaces was first noted to influence surgical and 
adjuvant treatment strategies by Ballantyne et al. Perineural invasion results in 
dysphagia secondary to involvement of the vagal trunk or pain and paresthesias along 
the territories of the trigeminal nerve [46]. PNI is mediated by the presence of nerve 
cell adhesion molecule (N-CAM) on the surface of squamous carcinoma cells, which 
engages in homophilic binding with N-CAM expressed in neural and perineural 
tissues. The presence of PNI is associated with a higher risk of metastasis to regional 
lymph nodes and poor local-regional control, cause-specific survival and overall 
survival. The association between PNI and local recurrence may result from either 
centrifugal or centripetal propagation of malignant cells along perineural spaces and 
away from the primary tumor [45]. Most primary tumors will only disseminate up to 2 
cm along the perineural space, although PNI 12 cm from the primary tumor has been 
reported [47].  
As a result PNI may allow malignant cells to evade surgical excision or 
radiotherapy and result in local recurrence. The percentage of mucosal HNSCC (Head 
& neck Squamous cell carcinoma)  positive for PNI varies widely in the literature 
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from 5% to 52% .This discrepancy may result from a tendency to identify PNI only 
when large, named nerves are involved or examined [47].  
However PNI of small unnamed nerves are the most frequent but may not 
result in clinical symptoms. The relationship between PNI and prognosis appears to be 
independent of nerve diameter [48]. Hence all  head and neck squamous cell 
carcinoma pathology specimens should be closely examined for PNI, even in nerves < 
1 mm in diameter (Fagan et al.) [45]. 
Vascular Invasion  
Vascular invasion is defined as the presence of neoplastic epithelium within an 
endothelium-lined channel. It has a reported incidence of over 50% in  HNSCCs.  
Vascular invasion correlates with the presence of concomitant cervical metastases in 
both univariate and multivariate models [49,50]. This risk associated for local regional 
recurrence in oral cavity, oropharyngeal, and laryngeal cancers. Vascular invasion has 
also been associated with increased risk of distant metastatic disease [51]. 
Imaging 
Imaging with 18F-fluorodeoxyglucose (FDG) PET scan may predict prognosis 
or more precisely response to interventions .Pre treatment PET/ CT scans have clear 
indications as discussed above . Gupta et al. and isle et al. independently confirmed 
my meta analysis the accuracy in identifying residue and hence the utility of post 
treatment PET –CT (12 weeks) scans in treatment recommendations [52,53]. However 
studies utilizing SUV values to predict response to radiotherapy or chemotherapy have 
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given conflicting results, consequently this imaging modality cannot be used for this 
indication [53]. 
Margin status 
Residual carcinoma at the  surgical margins is a risk factor for local recurrence 
in HNSCC. Positive margins in addition to indicating an error in surgical judgment, 
may also imply a  biologically aggressive tumor [55] .The  definition of “positive 
margins” is debatable and may include invasive tumor involving the initial surgical 
margin, invasive tumor involving the final surgical margin, invasive tumor 
approaching within 5 mm of the final surgical margin, carcinoma in situ at the final 
surgical margin, or dysplasia affecting the final surgical margin. Guidelines used in 
the United Kingdom define “negative” margins as invasive tumor more than 5 mm 
away from the surgical margin, “close” margins as invasive tumor within 1 to 5 mm 
from the surgical margin, and “positive” margins as tumor <1 mm from the surgical 
margin[56]. Looser et al. classified 1,775 cases according to final margin status  after 
excluding patients with gross residual disease, they identified 62 patients with 
microscopically positive margins, defined as either cancer within 0.5 cm of the 
margin, marked atypia or premalignant changes in the margin, carcinoma in situ in the 
margin, or invasive carcinoma in the margin.  All four of these groups experienced 
increased local recurrence rates, ranging from 64% in patients with invasive cancer at 
the margin to 85% for patients with carcinoma in situ at the margin, compared to a 
local recurrence rate of 32% in patients with negative margins [56].  
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The presence of positive margins predict local or local-regional recurrence for 
the sites lower lip, buccal mucosa, oral tongue,base of tongue, oropharynx and larynx. 
Whether or not margin status is an independent predictor of survival remains 
controversial, with two studies confirming an independent association, but six others 
failing to find an association. Margin status has not been shown to predict regional or 
distant recurrent disease [57]. Myers et al. demonstrated that use of intra operative 
frozen sections can identify  positive margins and thus allow resection of additional 
tissue to remove residual carcinoma and reduce the risk of local recurrence.  A 
concern regarding the use of intra operative frozen sections to determine margin status 
is its potential inaccuracy, with  false negative rate for oral cancer of 14 %. For these 
reasons most recommend adjuvant RT after re excision after positive margins [58].   
Nodal Prognostication  
Number of Positive Lymph Nodes 
The number, size, and location of positive cervical lymph nodes define the N 
stage for HNSCC and provide important information regarding prognosis and 
selection of treatment. The number of cervical lymph nodes histologically positive for 
squamous cell carcinoma provides one of the simplest, and most important, prognostic 
markers in head and neck cancer [63]. Mamelle et al. in multivariate analysis stratified 
by tumor site and patient age found the number of positive nodes was a significant, 
independent predictor of survival. Further extracapsular (ECE) spread and node 
location (upper vs. middle vs. lower neck) were significant predictors of survival. The 
nodal involvement appears to correlate with risk of regional recurrence and distant 
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metastasis. Studies have demonstrated a correlation between increasing number of 
positive nodes and regional recurrence in patients with advanced SCC who receive 
postoperative radiotherapy [61,62] . The relative importance of ECE versus number of 
positive nodes remains somewhat controversial.  Snow et al. found the number of 
positive nodes to predict poor survival independent of ECE, however the issue is 
disputed by others .Differences in treatment modalities and stratification of pathologic 
variables may explain some of the differences noted in these studies [65]. 
The extent of ECE can be stratified into the following three levels based on the 
morphology of the involved cervical lymph nodes: 
 A,  Macroscopic extracapsular spread with involvement of adjacent anatomic 
structures such as the internal jugular vein or skeletal muscle 
 B, Macroscopic extracapsular spread confined to the perinodal fibro-adipose tissue  
C, Microscopic extra- capsular spread. 
Johnsons et al   proposed that the presence of ECE in cervical lymph nodes 
may predict recurrence at the primary site. This hypothesis remains unresolved, 
Regardless of its relationship with local recurrence, ECE is a significant determinant 
of prognosis due to its association with increased risk of recurrence in the neck and 
distant metastatic disease[66]. This dictum is true for all head and neck sub sites .ECE 
continues to be a proven indication for adjuvant concurrent chemoRT . 
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Node Location 
Lymphatic spread from head and neck primaries follow step wise orderly 
spread to lower nodal  levels of the  neck . Mamelle et al. found that the presence of 
nodal metastases outside the primary nodal region independently decreased 5-year 
survival by more than 50% and nearly doubled the rate of distant metastasis[63]. The 
increased risk of regional recurrence, distant recurrence, and death associated with 
positive low cervical lymph nodes has been noted in several other studies of patients 
with HNSCC. Setton et al . reported that low-lying cervical metastases (levels IV, VB) 
were independent predictors of distant metastasis[54]. De Bree et al. found that 33% 
of HNSCC patients with low jugular lymph node metastases showed evidence of 
concomitant distant metastatic disease on preoperative CT of the thorax. 
Node Size 
The diameter of the largest metastatic cervical lymph node contributes to the 
assessment of N stage in HNSCC as it corresponds with total tumor burden. Carter et 
al. found that pathologic nodal size >2 cm correlated with increased risk for regional 
recurrence [68]. In contrast, Mamelle et al. found that nodal size increased the risk of 
distant metastases, with patients having nodal diameter <3 cm experiencing a distant 
metastasis rate of 22%, compared with 35% for patients with nodal diameter between 
3 cm and 6 cm and 49% for patients with nodal diameter >6 cm[64]. 
However these results have not been uniformly reproduced . Thus the diameter 
of the largest positive cervical lymph node may serve as a helpful clinical predictor of 
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outcome, but may not exert an independent prognostic effect when other pathologic 
factors are considered [68]. 
It is undisputed that nodal metastasis have a strong prognostic correlation, 
however  inspite of AJCC and TNM staging groups  recommending size criterion for 
nodal staging there are evidences that number of involved nodes and lower neck levels 
of nodal involvement too have prognostic implications .  
DEMOGRAPHIC PROGNOSTIC DETERMINANTS  
Age: 
Age  is a commonly considered covariate and is known to influence outcome in 
certain types of cancer. Patient age and its attendant comorbidities may influence the 
vigor of the immune response directed against the tumor and the patient’s ability to 
tolerate maximal therapy. A striking increase in the incidence of tongue and tonsillar 
cancer in adults under 40 years of age, has been noted  prompting additional interest in 
the risk factors, natural history, and optimal treatment of HNSCC in the young. The 
relationship of HPV to these malignancies has become well established .Young adults 
mostly females with HNSCC are less likely to report prior exposure to tobacco or 
alcohol.  
Regarding clinical outcome Siegelman-Danieli et al. reported, age did not 
influence relapse rates, cancer-free survival, or overall survival in univariate and 
multivariate analysis.  Verschuur et al. confirmed these in a retrospective study that 
age did not influence cause-specific survival.However, older patients were twice as 
likely to develop second primary SCCs of the upper aerodigestive tract (14% vs. 7%). 
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The effect of young age remains controversial[69]. Lacy et al.  found  that the 
recurrence risk was 50% less for patients under the age of 40  compared to those over 
the age of 40,  after controlling for TNM stage, primary tumor site, and comorbidity. 
The current literature suggests that young patients experience a prognosis that is either 
similar to or slightly better than that experienced by older patients [70]. Leon et al. 
reported that patients over the age of 70 were less likely to use tobacco and alcohol 
and more likely to be female and this correlated with a lower incidence of p53 
mutations in this population. However Leon et al. demonstrated that elderly laryngeal 
cancer patients experienced worse overall survival but cause-specific survival was not 
influenced by patient age[71]. Reviewing these evidences it can be concluded that 
elderly HNSCC patients may present with different risk factor profiles and are at 
increased risk of death from comorbid illness, but not an increased risk of death from 
cancer . The MACH NC metaanalysis reported that the benefit of adding concurrent 
chemotherapy to radiation decreased with advancing age. There was a significant 
overall survival advantage for patients up to 70 years old, but not for patients 71 yrs 
and above . In a more recent publication, MACH NC breaks down the benefit by 
primary site in addition to age [72,73]. 
Sex 
Sex is generally not considered as a significant determinant of survival in 
patients with head and neck cancer [74]. Most large series have failed to find a 
significant difference in outcome with respect to sex [75].  
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Comorbidity  
Comorbidity  refers to other diseases, illnesses, or conditions not directly 
related to the index cancer. Although not formally included in TNM staging, 
comorbidity directly influences  the care of cancer patients, selection of treatment 
modalities, and evaluation of treatment effectiveness. Multiple instruments have been 
utilized to characterize comorbidity in head and neck cancer patients, and proven 
superior. Piccirilo et al. used a simple  four-tiered classification as none, mild, 
moderate, and severe . In a prospective study of 1,086 patients with primary head and 
neck cancer, the presence of comorbidity was a significant, in- dependent predictor of 
2-year survival, even after controlling for age, sex, race, and stage. As compared to 
patients without co- morbidity, the mortality hazard ratio (HR) was 1.9 for patients 
with moderate comorbidity and 2.5 for patients with severe comorbidity. Similar 
results were reported in a study of 9,386 elderly Medicare beneficiaries with 
HNSCC[76,77]. Given the importance of comorbidity as a predictor of survival, 
efforts have been made to develop new systems for staging head and neck cancer that 
combine TNM staging with symptom- severity and comorbidity indices. The 
combination of comorbidity, symptom severity, and TNM stage holds promise for 
more accurate prognostication in head and neck cancer and merits prospective 
validation. 
Nutritional Status 
Malnutrition is common in patients with head and neck cancer and attributable 
to a number of causes including poor dietary habits, excessive alcohol consumption, 
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local tumor effects,  tumor induced cachexia, and the effects of various therapies[79]. 
Goodwin et al.  applied a prognostic nutritional index to patients with advanced head 
and neck cancer to determine the influence of nutritional status on whether nutritional 
status on survival. The  index considers serum albumin,  serum transferrin, triceps 
skin-fold thickness, and cutaneous  delayed hypersensitivity to mumps, streptokinase-
streptodornase, or candida. Goodwin et al. found that 89% patients with prognostic 
nutritional index >39% suffered major postoperative complications, compared to 14%  
of patients with prognostic nutritional index ≤39%. In addition, 64%  of the patients 
with prognostic nutritional index >39% died of their disease within 1 year, compared 
to 28%  of patients with prognostic nutritional index ≤ 39% [80]. In an analysis of six 
different nutritional parameters, 10% weight loss in the 6 months preceding surgery 
was the only significant, independent predictor of major postoperative complications 
by van bokhorst et al. in  patients with T2-4 carcinomas of the oral cavity, oropharynx, 
hypopharynx, and larynx. In a subsequent study, 5% weight loss in the 6 months 
preceding initial treatment for advanced HSNCC was identified as an independent 
predictor of poor disease-specific survival in men. Given the strong evidence for an 
association between  malnutrition and an increased risk of postoperative 
complications, there has been a renewed  interest  in evaluating the benefits of 
nutritional support [81]. A meta-analysis of 28 trials revealed that preoperative 
parenteral nutrition lowers the risk of major surgical complications and surgical 
mortality for patients with gastrointestinal  cancers. RTOG 90-03 examined the 
correlation between baseline nutritional support (BNS), radiation toxicity, and 
survival. BNS was defined as oral supplements, enteral feedings, or parenteral 
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nutrition used by the patient prior to beginning radiation. BNS was associated with a 
slightly lower risk of grade 3 or 4 radiation- induced mucositis  34% with BNS versus 
40% without BNS. However, even after adjusting for potential confounders, BNS was 
associated with a highly significant 1.5-fold increased risk of local-regional failure. 
This finding generated the hypothesis that nutritional support of head and neck cancer 
patients, though beneficial for their general medical condition and for minimizing 
toxicity of therapy, may actually exert a deleterious effect on cancer outcomes by 
providing the cancer with nutrients needed to resist the  effects of radiation 
therapy[82]. 
Anemia 
Anemia commonly occurs in patients with head and neck cancer  due to a 
number of reasons, including comorbid illness, intra operative blood loss, toxicity 
from chemo- therapy and/or radiation, and malignancy-associated anemia of chronic  
disease. Anemia may enhance radioresistance by inducing tumor hypoxia. A strong 
association between anemia and inferior local-regional control and survival among 
patients treated for HNSCC has been reported. This association has been found valid 
for both early and advanced disease independent of treatment modalities, including 
radiation alone, chemoradiation, surgery and postoperative radiation, and surgery 
alone [85].  
The optimal time point to assess anemia for the purposes of prognostication is 
unclear and varies widely throughout the literature. Options include pretreatment 
hemoglobin, mid radiation hemoglobin, postoperative hemoglobin, and drop in 
 
 
32 
 
hemoglobin concentration during radiation. It is likely all confer some degree of 
prognostic significance. The optimal hemoglobin cut point for defining anemia is also 
unclear, ranging from 10 to 14 g/dL, depending on the study [86]. Denis et al.  
concluded that 12.5 g/dL is the best cut point for predicting mortality. The benefit of 
treating anemic patients with recombinant erythropoietin (EPO) during radiotherapy 
has been studied [87]. Henke et al. in  found that administration of epoetin-b increased 
the median hemoglobin concentration from 11.7 g/dL pretreatment to 14.8 g/dL post 
treatment ,however, patients who received  epoetin-b experienced inferior local-
regional control (HR, 1.62; 95% confidence interval [CI], 1.22–2.14) and inferior 
overall survival (HR, 1.39; 95% CI, 1.05–1.84). RTOG 99-03 similarly found that 
taking epoetin increased hemoglobin concentration, by 1.66 g/dL in the experimental 
arm compared with 0.24 g/dL decrease in the control arm (p = 0.0001).It also reported 
no statistically significant difference in the primary endpoint of local-regional failure  
or overall survival[88].  
The administration of exogenous EPO  on control of HNSCC has shown in 
some studies a deleterious effect. The reasons for such an observation are currently 
unexplainable . Winter et al. demonstrated that 99% of HNSCCs express the EPO 
receptor and Lai et al. reported that treatment of HNSCC cell lines with EPO 
increased invasion and proliferation. Further a secondary analysis of the trial reported 
by Henke et al. demonstrated an increased risk of local-regional failure (relative risk, 
2.07; 95% CI, 1.27–3.36). In contrast, among EPO receptor negative tumors, 
administration of EPO did not affect local-regional control (relative risk, 0.94; 95% 
CI, 0.47–1.90) [89].  
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In summary, although there is a strong association between anemia and adverse 
outcomes, there is little evidence to suggest that modification of anemia through 
administration of growth factors produces a clinical benefit. The hypothesis that 
administration of EPO may stimulate tumor growth  should be realized before 
considering this medication. 
MOLECULAR PROGNOSTIC FACTORS 
The vast array of molecular factors studied in head and neck cancer can be 
divided into several broad categories. Proto oncogenes code for proteins that promote 
cellular proliferation. A proto- oncogene is transformed into an oncogene when its  
protein product becomes unresponsive to the normal regulatory processes that control 
cell division. Activation of proto- oncogenes occurs by point mutations, chromosomal 
translocations, or gene amplification. At the cellular level, an oncogene exerts a 
dominant phenotype over its proto-oncogene counterpart because only one copy of an 
oncogene is necessary to promote neoplasia. In contrast, tumor suppressor genes 
(antioncogenes) inhibit cellular proliferation. At the cellular level, both copies of a 
tumor suppressor gene must be disabled to promote neoplasia. Another class of 
markers includes proteins and growth factors that mediate the interaction between 
neoplastic cells and their local  microenvironment. In addition to these specific 
molecular markers expressed in neoplastic cells, other factors such as tumor ploidy 
and the rate of tumor cell proliferation may yield important prognostic information. 
The following molecular markers have been extensively studied 
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A, P53 
B, Cyclin D1 
C, EGFR 
D, Angiogenesis related factors 
P 53 
p53 is a transcription factor with tumor suppressor function that negatively 
regulates the cell cycle and serves to protect the integrity of the genome. The p53 gene 
resides on chromosome 17p13 and is composed of 11 exons spanning 20 kb in length. 
Activation of p53 occurs in response to a variety of cellular stressors, such as DNA 
damage, hypoxia, and cell cycle aberrations. These lead to p14ARF-mediated 
increases in p53 protein levels, with consequent cellular events, including G1 arrest, 
apoptosis, or senescence[90].  p53 protects the cell from propagating mutations to 
subsequent generations and is considered the “guardian of the genome.” Loss of p53 
function may contribute to tumor aggressiveness by promoting resistance to radiation 
and chemotherapy, accelerated growth in hypoxic conditions, and tumor 
neovascularization. Inactivation of p53 is a common event in HNSCC and may result 
from spontaneous or tobacco-induced mutations or from sequestration by cellular 
proteins such as mdm2241 or the E6 viral oncoprotein of HPV. 
Detection of p53 mutations has been attempted through both protein-based and 
DNA-based techniques others have utilized immune histochemistry (IHC). IHC is not 
an accurate method for detecting p53 mutations.  Studies correlating p53 mutation 
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with outcome in  HNSCC have suggested that p53 mutations are associated clinically 
with resistance to radiotherapy and chemotherapy . Koch et al. evaluated the 
prognostic significance of p53 mutations in exons 5 to 9  treated in patients with p53 
mutations and found were 2.4 times more likely to develop local-regional recurrence, 
similar to that conferred by the presence of positive cervical lymph nodes. The 
relationship to chemotherapy has been studied as well [91]. Temam et al. on 
multivariate modeling revealed that tumors with a mutant p53 gene were 70% less 
likely to experience major response to chemotherapy and, independently, tumors with 
high levels of p53 protein expression were 60% less likely to experience a major 
response. The correlation between p53 overexpression and resistance to chemotherapy 
persisted in the subset of patients with wild-type p53, suggesting that p53  conveys 
independent prognostic information in patients treated with chemotherapy[92]. This 
findings have been confirmed by others. Thus strong evidence supports a role for p53 
alterations in predicting poor initial response and long-term survival following 
treatment with chemotherapy [93,94]. 
Cyclin D1 
Cyclin D1 is a proto-oncogene located on chromosome 11q and serves as the 
rate limiting controller of G1-phase progression through the cell cycle. Cyclin D1 is 
the most commonly amplified oncogene in HNSCC, with approximately 35% of 
tumors revealing increased gene copy number in FISH analysis. Overexpression of 
cyclin D1 shortens the G1 interval and reduces the cell’s dependence on mitogens for 
proliferation. Overexpression of cyclin D1 may increase the aggressiveness of certain 
cancers by desensitizing cellular proliferation to inhibitory signals [95].  
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Although the literature remains conflicting, evidence suggests a relationship 
between cyclin D1 amplification and poor prognosis . In patients with clinically 
negative cervical lymph nodes, expression or amplification of cyclin D1 in the 
primary tumor increases the risk of cervical nodal metastasis by four- to eightfold. 
Bova et al. found cyclin D1 overexpression to predict increased risk for poor disease-
free and overall survival in patients with stage I to IV oral tongue SCC treated with 
surgery[96] . Similar results were reported by Michalides et al[97]. In contrast, some 
evidence suggests that cyclin D1 overexpression may actually increase the sensitivity 
of tumors treated with  radiation[97].  Yoo et al. and Hwang et al. reported that high 
cyclin D1 protein levels were associated with a threefold reduction in the risk of local-
regional recurrence among patients with laryngeal and nasopharyngeal cancers 
respectively treated with definitive radiation[98]. To summarise strong evidence 
suggests that cyclin D1 upregulation correlates with poor disease-free and overall 
survival in HNSCC.  
EGFR 
Several clinical reports have proven a correlation of EGFR overexpression with 
poor prognosis and radioresistance. Dassonville et al. reported that  EGFR expression 
independently predicted poor relapse-free survival in  stage I to IV HNSCC patients 
treated primarily with either chemotherapy or surgery[99] . Maurizi et al. reported  an 
independent relationship between EGFR protein expression and poor disease-free and 
overall survival in stage I to IV laryngeal SCCs treated primarily with surgery[100].   
Similar results have been reported by Grandis and chung et al [101] .Both IHC and 
FISH appears to be the techniques of choice for use in these studies. Thus the 
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cumulative evidence suggests that EGFR protein overexpression or gene amplification 
is associated with poor prognosis .EGFR overexpression also seem to confer 
radioresistance, Ang et al. reported on RTOG study 90-03 that overexpression of 
EGFR was associated with poor local-regional control, disease- free survival, and 
overall survival in multivariate analysis[102]. In addition, growing evidence suggests 
that accelerating the course of radiotherapy may mitigate the adverse effect of EGFR 
overexpression on local-regional control. Benzen et al  demonstrated altered 
fractionisation schedules may overcome EGFR induced radioresistance .   
Targeting EGFR pathway with monoclonal antibodies  offers exciting 
alternative treatment oppurtunities [103]. Further to the study by Bonner et al. and the 
EXTREME study cetuximab alone or in combination with chemotherapy and or 
radiotherapy has been incorporated in to major guidelines as first line / metastatic 
treatment option for head and carcinomas [104,105]. 
Angiogenesis-Related Markers 
Tumor angiogenesis is the sprouting of new abnormal vasculature from a 
preexisting endothelium and permits tumor growth beyond microscopic size. 
Angiogenesis is promoted by cytokines, like the VEGF family, basic and acidic 
fibroblast growth factor (bFGF, aFGF), interleukin-8 (IL-8) and platelet-derived 
endothelial cell growth factor (PD-ECGF). The vascular endothelial growth factor 
family comprises of 5 members including VEGF-A, VEGF-B, VEGF-C, VEGF-D, 
and VEGF-E. Among these VEGF-A plays a central role in  angiogenesis while others 
like VEGF-C are  potent inducer of lymphangiogenesis. Three receptors namely 
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VEGFR-1, VEGFR-2, and VEGFR-3 bind VEGFs. VEGF receptors 1 and 2 are 
expressed by vascular endothelium, while VEGFR-3 is present on the lymphatic lining 
endothelium [106,107]. 
Over- expression of VEGF is the result of tumor hypoxia-induced upregulation 
of transcription factors and eIF4E-mediated increase  in  translation. Hypoxic tumors 
are generally radioresistant hence VEGF protein levels in these tumors may surrogate 
for hypoxic radioresistance. Tumor neoangiogenesis may augment a tumor’s 
metastatic potential by permitting access to greater endothelial surface area, this 
increases the possibility of hematogenous  dissemination.  Expression of both VEGF 
and PD-ECGF is known to correlate with micro vessel density in HNSCC and 
elevated tumor MVD as assessed via IHC has been postulated to predict  risk of 
concomitant cervical lymph node metastasis in oral  and nasopharyngeal cancers .It 
also correlates  with risk of regional relapse in clinically node negative oral cancers  
treated with surgery. However studies are conflicting with regards to overall survival 
.A critical metaanalysis of 12 studies including 1,002 patients concluded that high 
levels of VEGF expression assessed via IHC correlated with a highly significant 1.88-
fold increased risk of 2-year mortality.  The strong and reproducible association 
between elevated expression of VEGF and adverse outcomes have encouraged trials 
to assess the possible therapeutic benefit of anti-VEGF therapy such as bevacizumab 
[108,109].  
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STUDY RATIONALE 
Eighty percent of Indian head and neck cancers present late.  Early diagnosis 
and treatment remains the most effective disease control strategy .Unfortunately as 
most are diagnosed at an advanced stage constraining physicians to develop 
alternative approaches to improve outcome. Risk stratification is an established 
concept in cancer care management. It helps to identify high risk groups, individualize 
treatment options, select patients for clinical trials and permits optimal use of scant 
resources. A risk adapted approach to cancer management is routine in several 
cancers, unfortunately a robust risk stratification system for head and neck cancers is 
deficient .This study hopes to cater to this situation by initially identifying 
pretreatment factors that affect prognosis and their subsequent feasibility as a risk 
stratification tool for head and neck cancers  
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                                                          AIM  
1. To evaluate the influence of vital pre treatment variables employed in 
evaluation and treatment of head and neck carcinomas in predicting prognosis . 
2. To assess the feasibility of stratifying head and neck cancer patients into risk 
groups based on significant variables affecting survival endpoints . 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
MATERIAL AND METHODS 
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METHODS 
The study was done at center for oncology, Govt. Royapettah hospital between 
October 2012 and January. 2015. Patients attending the cancer OPD were assessed for 
inclusion in the study. The eligibility criteria was set as given below 
INCLUSION CRITERIA: 
1, Biopsy proven non metastatic carcinomas of  oral cavity, pharynx  and larynx 
2, Squamous cell carcinoma – Histology 
EXCLUSION CRITERIA: 
1, Salivary gland carcinomas 
2, Nasopharyngeal carcinomas 
3, Non squamous histology types 
4, Esophageal and OGJ tumors 
5, Metastatic disease at presentation 
6, Second primary cancers 
All patients conforming to the eligibility criteria as  above and consenting to 
the study were enrolled . The following evaluation was done in order 
1, Demographic data collection 
2, comprehensive examination  including 
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                                                       - History 
                                                       -Co morbidity evaluation 
                                                       -General physical examination 
                                                      -Biopsy 
                                                     - Endoscopic studies as appropriate 
                                                     -Imaging with chest X ray and CT/ MRI of   
                                                       the local part 
                                                    - Lab investigations complete blood count, 
                                                      Renal and liver function tests                    
3, Stage assignment 
4, Treatment 
The study population was treated with stage appropriate single or multimodal 
treatment protocols as per standard treatment recommendations. The protocols 
included primary chemoRT for the pharyngeal cancers followed by surgery for 
salvage . For early  oral cavity cancers surgery alone or surgery followed by adjuvant 
CRT  and for locally advanced disease surgery followed by CRT was administered. 
Alternatively  chemoRT with a review at 50 Gys was done in some patients as an 
institution policy and subsequent management decided based on response assessment . 
Chemotherapy when employed in concurrent setting used predominantly cisplatin in a 
dose of 50 mgs/m2, some received two 3 weekly courses of cisplatin 75 mg/ m2 and 5 
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FU 600 mgs /m2.Radiation therapy was delivered using a tele cobalt unit to a dose of 
66Gy in the definitive setting and as 50 Gys adjuvantly. Toxicity relayed data 
including treatment related deaths were noted. Dynamic treatment related data like 
weight loss during treatment, need for nutritional support, treatment defaults and 
interruptions were prospectively collected  .The study cohort was followed till the end 
of study period with 2 monthly clinical examination, yearly chest x rays and 
endoscopic evaluation and CT imaging were done as symptom directed procedures. 
Time to recurrence and death were recorded . Residual and recurrent lesions were 
managed as per standard head and neck treatment protocols. 
DEFINITING RISK FACTOR VARIABLES 
To facilitate statistical analysis of the collected data it is mandatory that 
variables are categorized into groups, the following scheme was applied 
AGE: segregated in to less than or more than 55 yrs of age 
SEX: into male and female groups 
SITE: As oralcavity, oropharynx ,hypopharynx and larynx 
STAGE :  Standard AJCC/TNM  staging of Head and neck sites -10 th edition was 
used 
PS : ECOG performance status 0-1, as group 1 and more than or equal to 2 as group 2 
BODY MASS INDEX : as BMI less than 25 and more than 25 
TUMOR GRADE : as grade 1,2 and 3 (WHO ) 
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COMORBIDITY INDEX: as Adult comorbidity evaluation -27 score ,into group 1 if 
score was 0-1 and group 2 if more than or equal to 2 
HEMOGLOBIN :less than 10 gms or more than 10 gms/DL 
TOTAL COUNT : less than 4000/mm3,4000-11000/mm3 and more than 11,000/mm3 
PLATLETS :Normal -1.5 to 3 lakhs and values outside reference range as abnormal 
SERUM ALBUMIN : less than 3.5 gms or more than 3.5 gms/DL 
TREATMENT RELATED WEIGHT LOSS : less than or equal to 5 kgs or more than 
5 kgs, recorded before, during  and one week after completion of primary treatment 
(RT ) and if primary surgery is applied weight is evaluated before and 2 weeks after 
surgery ,measured using standard weighing scale. 
NUTRITIONAL INTERVENTION : Defined as requiring ,nasogastric tube insertion 
or surgical feeding jejunostomy prior to or during treatment period 
(radiotherapy).patients requiring nasogastric tubes for feeding after oral surgery were 
excluded . 
TREATMENT INTERUPPTION: Failure to complete planned multimodal treatment 
including surgery due to non iatrogenic indications or defaulting more than 2 cycles of 
weekly concurrent chemotherapy, or 1 cycle of combination chemotherapy or more 
than 3 consecutive fractions of radiotherapy . 
Survival time was calculated from the start of treatment to the end of follow up 
period. Patients lost to follow up and death due to disease specific or treatment related 
events were deemed censored and included for analysis .  
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STATISTICAL ANALYSIS: 
The Kaplan Meier survival method was used for survival analysis and log rank 
test for the univariate analysis of  the probable prognostic variables. A P value of  or 
less than or equal to 0.05 as deduced by a 2 tailed test was considered a significant 
result. All variables showing significance by univariate analysis were subjected to 
multivariate analysis by the cox’s proportional regression analysis .The chi square test 
and Fishers exact test were used as appropriate. All statistical analysis were performed 
using SPSS  software (version 22 IBM ) 
 
 
  
 
 
ANALYSIS AND RESULTS 
 
 
 
 
 
 
 
 
46 
 
RESULTS 
A  total of 212 patients were enrolled ,treated and followed up for the study 
between November 2012 and January 2015. 
Patient Demographics 
The age of the patients ranged from 23 -83 yrs with a median of 54 yrs .The age 
distribution is as shown below 
 
                                 
There were 154 (71 %) males and 59 (29%) females in the study as shown  
 
 
 
 
 
 
 
AGE 
GROUPS 
SAMPLES 
20-29 4 
30-39 24 
40-49 44 
50-59 69 
60-69 50 
70-79 17 
80-89 4 
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Disease characteristics 
Regarding site specificity oral cavity cancers  were the commonest (63 %), 
followed by hypopharynx (16 %),oropharynx (14 %), and larynx (6 %) . 
 
                               
Overall majority of the patients had locally advanced cancers with stage IV 
(55%),and stage III(22 %) disease. Early head and neck cancers constituted about 21% 
of the study with stage I and stage II cancers contributing 6% and 14 % respectively. 
Most of the stage IV lesions had T4a disease or nodal positivity none had metastatic 
disease at presentation  
 
                   
SITE SAMPLES 
Oral cavity 134 (63%) 
Hypopharynx 34 (16 %) 
Oropharynx 30 (14% ) 
Larynx 14 (6 %) 
Stage I 14 (6%) 
Stage II 33 (14%) 
Stage III 48 (22%) 
Stage IV 117 (55% ) 
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Most of the lesions were moderately differentiated carcinomas (65 %),while 
poorly differentiated tumors and well differentiated tumors comprised of 8% and 26% 
respectively . 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
GRADE SAMPLES 
I 56 (26%) 
II 138 (65%) 
III 18 (8%) 
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UNIVARIATE ANALYSIS 
AGE: 
The median age at presentation was 54 years .The age group 51-60 had the 
highest number of samples but suffered only 19 (30 %) adverse events, however the 
proportional adverse event rate was higher in the younger age groups with 21-30,31-
40, 41-50 age groups showing  4(80%),13 (39%),21(36%) death rates. On univariate 
analysis age as a prognostic variable was not significant with a P=0.379 by the log 
rank test. 
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SEX: 
There were 153 males and 59 females in the study. Forty two  (76.3%) males 
and 13 (23.7%) females had adverse survival outcome during the study period, 
however the sex specific death rate was essentially similar between the groups at 
27.9% and 22% .The median survival during study period was 13 (95% CI 12-18 
mon) and 14 months (95% CI 12-16 mon) for males and females respectively. Sex 
group as a prognostic variable was not significant by univariate analysis with  P= 
0.1472 (log rank test ) . 
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SITE: 
Oral cavity was the commonest site followed by hypopharynx, oropharynx and 
larynx. The adverse event rate was highest in oral cavity site 31 (56%) reflecting 
sample size distribution, followed by hypopharynx 11 ( 21%), oropharynx  11 (19.7%) 
and larynx 2 (1.6 %), but the proportional event rate was highest in oropharynx  50% 
and hypopharynx  47% followed by oral cavity 32% and larynx 14% respectively. The 
median site specific survival during the study period was 13 months (95% CI 11-19) 
for oral cavity, 12 months (95% CI 13-17) for hypopharynx, 7 months (95% CI 4-9) 
for oropharynx  and 17 months (95% CI 16-18 )for larynx. Site as a prognostic 
variable was not significant with  P=0.614 (log rank test ). 
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STAGE: 
Most of the patients had locally advanced cancers with a predominance of stage 
IV and III disease. The proportional adverse event rate was highest in stage IV, 
followed by stage III, with no events in stage I patients. Stage as a prognostic variable 
returned a P value less than 0.001 by the log rank test . 
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GRADE: 
Most tumors were of grade 2 followed by grade 1 and 3 respectively. The 
median survival with regards to grade of tumor was 14 months, 09 months and 6 
months during the study period. The grade as a prognostic variable by univariate 
analysis was highly significant with P=0.005 (log rank test). 
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PERFORMANCE STATUS 
ECOG performance status as prognostic variable was categorized as PS 0-1 
and PS ≥ 2.Both groups had adverse events with higher proportional rate in  the 
second group , pre treatment performance status as a prognostic variable was  
significant with P=0.049 (log rank test ). 
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BODY MASS INDEX : 
 BMI was categorized as two groups BMI < 25 and BMI ≥ 25, after group 
assignment analysis was done. Majority of the patients had normal BMI .Despite the 
fact that the patients in low BMI group had a higher proportional mortality, the log 
rank test did not show a significance for BMI as the P was equal to value to 0.070 . 
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COMORBIDITY 
Comorbidity as a prognostic variable was assessed using the Adult comorbidity 
evaluation score version 27.Groups were segregated as ACE score 0-1 and ≥ 2. Higher 
proportional mortality was observed in the  second group (figure below )but an impact 
on survival time was not evident with P =0.061(log rank test ). 
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HEMOGLOBIN 
 Pre treatment hemoglobin was grouped as <10 gms and ≥10 gms/dl. Patients 
with anemia had a higher adverse proportional outcome and hemoglobin as prognostic 
variable was significant with P=0.005 (log rank test). 
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TOTAL WBC COUNT AND PLATLET COUNT 
Total leucocyte count was grouped as <4000/mm3,4000-11000/mm3 and > 
11000/ mm3 .Platelet count was labeled as normal or abnormal and normal value 
defined as 1.5 to 4 lakhs ,values outside this range were deemed and grouped as 
abnormal. Both total leucocyte and platelet counts were not significant prognostic 
variables with P values of 0.751 and 0.160 respectively (log rank test). 
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SERUM ALBUMIN 
Hypoalbuminemia is a sign of malnutrition and pre treatment low serum 
albumin may affect survival outcomes .In this study serum albumin was categorized 
as 2 groups < 3.5 gms or ≥ 3.5  gms /dl for the purpose of assessment as prognostic 
variable. A higher proportional mortality was observed in hypoalbuminemia group 
with none surviving till the end of study period. Serum albumin as a prognostic 
variable was just significant including third decimal with P =0.046 (log rank test). 
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TREATMENT RELATED WEIGHT LOSS 
 The above variable was defined as the difference in weight before and on 
completion of primary treatment modality. The patients were grouped as those with < 
5kgs weight loss and ≥ 5 kgs weight loss. Treatment related weight loss as a 
prognostic variable was significant with P=0.011 (log rank test) .A higher mortality 
was observed in group 2 with only one surviving till the end of study period . 
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NUTRITIONAL INTERVENTION /SUPPLEMENTATION 
 Overall 48(22.6% ) required some form of nutritional intervention. Most were 
in the form of nasogastric tube insertion for feeding while others required a surgical 
feeding jejunostomy. A higher proportional mortality was observed with the group 
requiring nutritional intervention. This variable on univariate analysis was significant 
with P = 0.040 (log rank test). 
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TREATMENT INTERUPPTION 
 The study had a stringent definition for treatment interruptions and 
consequently 52(25%) interruptions were identified .Only 8 (15 %) patients with 
interruptions were alive at the close of the study. Treatment interruption as a risk 
variable was significant with P =0.019 (log rank test). 
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UNIVARIATE ANALYSIS SUMMARY TABLE 
SNO VARIABLE PATIENTS % 
P VALUE 
LOG RANK 
TEST 
SIGNIFICANCE 
1 
AGE < 55 yrs 
         ≥ 55 yrs 
96   (46%) 
116 (54%) 
P = 0.379 NO 
2 
MALE 
FEMALE 
154 (71%) 
59   (29%) 
P = 0.147 NO 
3 
SITE 
       Oral cavity 
       Hypopharynx 
       Oropharynx 
       Larynx 
 
134 (63%) 
34   (16%) 
30   (14%) 
14   (06%) 
P = 0.614 NO 
4 
STAGE I 
            II 
           III 
           IV 
14   (06%) 
33   (15%) 
48   (22%) 
117 (55%) 
P = 0.001 YES 
5 
PS O-1 
      ≥ 2 
165 (77%) 
47   (23%) 
P = 0.049 YES 
6 
GRADE  1 
               2 
               3 
56   (26%) 
138 (65%) 
18   (08%) 
P = 0.005 YES 
7 
BMI < 25 
        ≥ 25 
7     (03%) 
205 (97%) 
P = 0.070 NO 
8 
ACE 0-1 
         ≥ 2 
192 (90%) 
20   (10%) 
P = 0.061 NO 
9 
Hb  < 10 gms 
       ≥ 10 gms 
136 (64%) 
75   (36%) 
P = 0.005 YES 
10 
Sr.Albumin < 3.5 gms 
                     ≥ 3.5 gms 
12   (05%) 
200 (95%) 
P = 0.046 YES 
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11 
TOTAL WBC < 4000 
                       4000 – 
11OOO 
                       ≥ 11000 
2     (02%) 
198(93%) 
12  (05%) 
P = 0.751 NO 
12 
PLATELET COUNT 
Normal 
                              
Abnormal 
199(93%) 
14  (07%) 
P = 0.160 NO 
13 
WEIGHT LOSS < 5 
kgs 
                          ≥ 5 kgs 
167(78%) 
45  (22%) 
P = 0.011 YES 
14 
NUT. 
INTERVENTION  
          YES 
          NO 
 
48  (22%) 
164(78%) 
P = 0.040 YES 
15 
Rx INTERUPPTION 
           YES 
           NO 
 
52  (25%) 
160(75%) 
P = 0.019 YES 
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MULTIVARIATE ANALYSIS 
 A total of 15 variables were subjected to univariate analysis by the log rank test 
.Eight variables were significant prognostic factors with P ≤ 0.05 (second 
decimel).These were then incorporated into a cox’s regression model and multivariate 
analysis done. The results are as shown  below. 
S NO VARIABLE P VALUE SIGNIFICANCE 
1 STAGE IV P = 0.041 Yes 
2 GRADE 3 P = 0.006 Yes 
3 HEMOGLOBIN < 10 gms P = 0.598 No 
4 Sr.ALBUMIN < 3.5 gms P = 0.583 No 
5 TREATMENT RELATED 
WT.LOSS > 5 kgs 
P = 0.047 Yes 
6 NUTRITIONAL INTERVENTION P = 0.358 No 
7 TREATMENT 
INTERUPT/DEFAULT 
P = 0.001 Yes 
8 PERFORMANCE STATUS ≥ 2 P = 0.038 Yes 
  
 Five variables stage IV, grade 3, ECOG performance status, treatment related 
weight loss and treatment interruption/default had significant P values as above and 
were proven to influence survival. 
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RISK STRATIFICATION 
 
 A risk stratification scheme was designed incorporating these five prognostic 
variables .Three risk categories were identified and designated  as favorable ,low and 
high risk groups. The Favorable risk group (group-0 ) had none of the  risk factors ,the 
low risk (group -1) was defined as having at least any two prognostic factors and high 
risk ( group-2) as having three or more risk factors. The entire study cohort was then 
retrospectively segregated based on the above risk stratification and survival analysis 
done using Kaplan Meier analysis and the log rank test .The results show the best 
survival for the favorable risk group ,followed by the low risk group. The high risk 
group had the worst survival, with P = 0.001 (log rank test ).The estimated survival 
curve is  shown below. 
 
 
                                                         
 
 
  
 
 
DISCUSSION 
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DISCUSSION 
 
 Head and neck cancers as a group are the commonest cancers in India 
nationwide. Surgery or radiation therapy is equally effective in early disease with 
good survival rates, locally advanced disease requires a multimodality treatment 
approach, unfortunately with suboptimal survival [110-111]. Most patients in India 
present with locally advanced disease .Early detection and treatment is an effective 
survival improvement strategy but its implementation in India has been difficult with 
several impediments. An alternative scheme to improve survival is a risk adapted 
treatment approach there by individualizing treatment and prioritizing  resources to at 
risk patients. This strategy has been proven to be effective in other cancers but has not 
been applied to head and neck cancers [112,113].    
This study was attempted with the intention of creating a practically feasible 
risk prediction model based on prognostic factors for the stratification of patients with 
non metastatic head and neck cancers into homogenous  risk groups, facilitating a 
more accurate prediction of  outcome. The anticipated benefits of risk stratification are 
1, Identification of  patients at risk of suboptimal survival outcomes 
2, Prioritizing treatment resources to at risk patients 
3, Close monitoring of therapy and early identification of iatrogenic adverse           
events 
4, Aggressive multimodal treatment of high risk patients to improve survival 
5, Modifying surveillance scheme to detect early failure 
6, Establishing selection criteria for future clinical trials  
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PATIENT CHARACTERISTICS 
The patient characteristics of the study group was typical of patients attending 
any tertiary cancer  care treatment facility in India. Males outnumbered females  in a 
ratio 3:1,The median age of presentation was the sixth decade and oral cavity was the 
commonest head and neck cancer site. Most patients were from urban or suburban 
localities and tobacco induced cancers predominated in the study population. These  
findings are in concordance with other authors. 
 
DISEASE CHARACTERISTICS 
 The Buccal mucosa was the most frequent subsite followed by the  anterior 
tongue. Hypopharynx was the second commonest site followed by oropharynx and 
larynx seventy seven percent of the patients had locally advanced disease (stage III 
and IV) with early disease constituting about 23 % only. All patients had squamous 
cell histology as per inclusion criteria and most tumors were moderately differentiated 
tumors (65 %). 
 
PROBABLE PROGNOSTIC VARIABLES 
A list of 15 variables were chosen for analysis based on published literature. 
The list included previously unevaluated variables like, treatment interruption and 
requirement for nutritional intervention. Age as a prognostic variable with several 
cutoff criteria has been reported, Hsieh et al. and stokes et al. found age > 65yrs to 
affect survival [114]. Thrombocytosis has been shown to affect survival in several 
cancers. Thrombocytosis has been reported to predict poor prognosis in esophageal 
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cancer (okuzumi et al. [122] ) and progression in oral cavity squamous cell 
carcinomas (Lu et al ) [123]. Sanabria et al found comorbidity as prognostic variable 
with an ACE-27 score of >2  correlating with survival in head and neck cancers [128]. 
Arce et al. reported that the female sex to be an independent predictor of survival in 
head and neck cancers [129]. Takenaka et al. published that a median BMI of 21.4 
was predictive of poor survival independent of head and neck tumor site and stage 
[130] . Chen et al. reported a significant correlation between T-stage/metastasis and 
monocyte or platelet count. Monocytosis, anemia, and thrombocytosis were 
demonstrated to have a cumulative effect on the prognosis of head and neck cancer 
patients [124] .In spite of data from above studies age, sex, site, body mass index, 
comorbidity, total leucocyte count and thrombocyte counts were not found to be 
significant prognostic variables in this study. These findings are in accordance with 
risk stratification study by Hsieh et al. In the present study ECOG performance status, 
stage, tumor grade, anemia, hypoalbuminemia, treatment related weight loss, 
nutritional intervention and treatment interruption were found to be significant 
variables affecting survival. 
PROGNOSTIC VARIABLES  
The above eight variables with significant P values were subjected to 
multivariate analysis and Tumor stage IV, grade 3, ECOG performance status ≥ 2, 
treatment related weight loss more than 5 kgs,  and treatment interruption correlated 
independently with poor survival. Anemia, hypoalbuminemia, and need for nutritional 
intervention were not associated with adverse survival on multivariate analysis. 
Mehrotra et al. noted primary site, anemia and age ≥ 70 yrs as significant prognostic 
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variables on multivariate analysis [131]. Hsieh et al. reported in their retrospective 
study three variables age ≤ 65 yrs, PS ≥ 2 and elevated serum lactate dehydrogenase 
levels as significant prognostic variables. Urba et al. attempted to risk stratify 
recurrent and metastatic head and neck cancers and found among other factors age ≤ 
65 yrs, ECOG PS ≥ 2 and oral cavity site as predictive of influencing overall survival 
[132]. In the study by cojocariu et al. tumor size, site, grade and nodal status were 
reported as prognostic variables along with overexpression of EGFR [133]. Degree of 
differentiation alone as a prognostic variable has been reported in oral cavity 
carcinomas by Shi et al. and Pathak et al. however other studies (Fang et al.) are 
conflicting [134,136] .Treatment related weight loss is a recognized prognostic 
variable (Johnston et al.) weight loss more than 10% during radiotherapy is known to 
be associated with adverse survival and poor quality of life (Languis et al.)[137,138]. 
It is clear from the above discussion there appears to be no consistently reproducible 
prognostic variables however most studies have reported that Tumor stage, grade, 
ECOG performance status and treatment related weight loss as significant 
determinants of survival .The results of the present study is largely in agreement with 
published evidence. 
 
RISK STRATIFICATION 
In the present study a risk stratification scheme was designed incorporating 
these five prognostic variables and patients stratified as favorable, low and high risk 
groups. A significant survival difference was predicted by the scoring system. Hsieh et 
al used only a three variable scoring system and demonstrated significant risk 
prediction if more than 2 adverse factors were present [114]. They were subsequently 
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able to validate their score .The proposed risk stratification has only one common 
variable (ECOG PS) with that of Hsieh et al., the differences might be due to different 
definitions for age at risk between the two studies ( 55 Vs 65 yrs), incorporation of 
novel prognostic variables in the present study and nonspecific nature of serum lactate 
dehydrogenase (used by Hsieh et al) .An explanation for this study to identify more 
risk factors than other studies is its prospective nature. A major advantage of the 
proposed scoring system is that it incorporates dynamic treatment related parameters 
(weight loss and treatment interruption) permitting continual risk assessment during 
the entire treatment period. Another exciting feature of this risk scheme is that it 
contains modifiable risk factors (weight loss and treatment interruption) which permits 
the possibility of appropriately timed treatment interventions to improve outcome.    
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CONCLUSION 
 
1. Risk stratification of head and neck cancer patients using  certain patient, tumor 
and treatment related variables is feasible. 
2. Tumor stage, degree of tumor differentiation, ECOG performance status, 
treatment related weight loss and treatment interruption are proven prognostic 
factors affecting survival outcomes. 
3. Risk categorization of head and neck cancer  patients into favorable risk, low 
and high risk groups using the above prognostic factors and scoring scheme 
correlates with differing survival outcomes. 
4. Further validation of these  study findings on a separate patient cohort is 
suggested before considering practical application.         
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